Motac provides highly-specialised preclinical services for the pharmaceutical and biotechnology industries to support the discovery and development of therapeutics for neurological and psychiatric disorders. Motac has extensive expertise and world-class research capabilities in neurodegenerative conditions, particularly Parkinson’s disease, other movement disorders and cognitive disorders. We specialize in preclinical proof-of-concept and efficacy studies.

Motac has unparalleled ability to offer access to the best available models of these conditions, underpinned by first-class scientific understanding, yet offered in a commercial environment with an emphasis on quality and timeliness.

Motac also has an intellectual property portfolio protecting a number of new chemical entities and novel therapeutic targets for the treatment of movement disorders, which we are developing through strategic alliances and partnerships.